A Phase 3 interventional study of Mirikizumab and Placebo in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 502 sites in 35 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 2nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Rubix LS · Sites in United States
Ages 60–99
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2018.
This study's enrollment of 1,281 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 172 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
16 studies in Colitis, Ulcerative by Eli Lilly and Company: 5 open now, 7 under way, 3 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 8 in phase 3, and was the 2nd registered.
Eli Lilly and Company’s Colitis, Ulcerative studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 16 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
Drug: Placebo
300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
Drug: Mirikizumab
Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
Drug: Placebo
300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
Drug: Mirikizumab
Administered IV
Also known as: LY3074828
Administered IV
Percentage of Participants With Clinical Remission at Week 12
Clinical remission at week 12 is defined as achieving a modified Mayo score (MMS) subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability), excluding consideration of Physician's Global Assessment (PGA). Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The confidence interval of 99.88% was chosen to match the significance level.
Time frame: Week 12
Percentage of Participants With Clinical Response at Week 12
Clinical response at week 12 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).The MMS ranges from 0 to 9 points,with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.
Time frame: Week 12
Percentage of Participants With Endoscopic Remission at Week 12
Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 12. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The Mayo endoscopic score ranges from 0 to 3 points, with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.
Time frame: Week 12
Percentage of Participants With Symptomatic Remission at Week 12
Symptomatic remission at week 12 is defined as a Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The confidence interval of 99.88% was chosen to match the significance level.
Time frame: Week 12
Percentage of Participants With Symptomatic Response at Week 12
Symptomatic response at week 12 is defined as ≥30% decrease from baseline in the sum of stool frequency and rectal bleeding subscores. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The sum of stool frequency and rectal bleeding subscores ranges from 0 to 6.
Time frame: Week 12
Percentage of Participants With Histologic Remission at Week 12
Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).
Time frame: Week 12
Percentage of Participants With Endoscopic Response at Week 12
Endoscopic response at week 12 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore. The Mayo endoscopic subscore ranges from 0 to 3 points, with higher scores representing more severe disease.
Time frame: Week 12
Change From Baseline to Week 12 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS)
The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Fecal Calprotectin
Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).
Time frame: Baseline, Week 12
Pharmacokinetics (PK): Clearance of Mirikizumab
Clearance of mirikizumab was evaluated. Clearance is estimated based on concentration data collected in the time frame of 0-12 weeks.
Time frame: Predose on week 0, week 4, week 8 and post dose on week 0, 4 and 12
Main study: Participants were randomized in a 3:1 ratio to 300 milligrams (mg) of mirikizumab intravenously (IV) every 4 weeks (Q4W) or placebo IV Q4W. China Maximized Extended Enrollment (ME2): This is an extension phase of the main study, with an additional 166 participants enrolled in China. Safety was monitored and data was reported under Adverse Events (AE) section.
| Milestone | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort |
|---|---|---|---|---|
| Started | 322 | 959 | 41 | 125 |
| Received at least one dose of study drug | 321 | 958 | 41 | 125 |
| Completed | 285 | 920 | 36 | 116 |
| Not completed | 37 | 39 | 5 | 9 |
| Withdrew: Adverse event | 23 | 15 | 3 | 2 |
| Withdrew: Withdrawal by subject | 8 | 5 | 1 | 0 |
| Withdrew: Lack of efficacy | 5 | 5 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 5 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 |
| Withdrew: Insufficient diary data | 0 | 2 | 0 | 0 |
| Withdrew: Non- compliance to protocol | 0 | 1 | 0 | 0 |
| Withdrew: Covid-19 related study disruption | 0 | 2 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 2 |
Clinical remission at week 12 is defined as achieving a modified Mayo score (MMS) subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability), excluding consideration of Physician's Global Assessment (PGA). Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The confidence interval of 99.88% was chosen to match the significance level.
| percentage of participants | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 12 | 13.3 (6.9 to 19.6) | 24.2 (19.5 to 28.9) |
Clinical response at week 12 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).The MMS ranges from 0 to 9 points,with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.
| percentage of participants | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Percentage of Participants With Clinical Response at Week 12 | 42.2 (32.9 to 51.5) | 63.5 (58.2 to 68.8) |
Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 12. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The Mayo endoscopic score ranges from 0 to 3 points, with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.
| percentage of participants | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 12 | 21.1 (13.4 to 28.8) | 36.3 (31.0 to 41.6) |
Symptomatic remission at week 12 is defined as a Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The confidence interval of 99.88% was chosen to match the significance level.
| percentage of participants | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Percentage of Participants With Symptomatic Remission at Week 12 | 27.9 (22.8 to 33.0) | 45.5 (42.2 to 48.8) |
Symptomatic response at week 12 is defined as ≥30% decrease from baseline in the sum of stool frequency and rectal bleeding subscores. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The sum of stool frequency and rectal bleeding subscores ranges from 0 to 6.
| percentage of participants | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Percentage of Participants With Symptomatic Response at Week 12 | 52.4 (46.7 to 58.1) | 72.0 (69.0 to 75.0) |
Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).
| percentage of participants | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Percentage of Participants With Histologic Remission at Week 12 | 15.6 (11.5 to 19.8) | 29.3 (26.2 to 32.3) |
Endoscopic response at week 12 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore. The Mayo endoscopic subscore ranges from 0 to 3 points, with higher scores representing more severe disease.
| percentage of participants | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 12 | 36.1 (30.6 to 41.5) | 55.4 (52.1 to 58.7) |
The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).
| score on a scale | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Change From Baseline to Week 12 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) | -1.63 ± 0.141 | -2.59 ± 0.083 |
The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).
| score on a scale | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Change From Baseline to Week 12 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score | 25.21 ± 1.798 | 38.42 ± 1.108 |
Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).
| milligram per kilogram (mg/kg) | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W |
|---|---|---|
| Change From Baseline to Week 12 in Fecal Calprotectin | -939.69 ± 196.557 | -1875.29 ± 116.138 |
Clearance of mirikizumab was evaluated. Clearance is estimated based on concentration data collected in the time frame of 0-12 weeks.
| Liters per Hour (L/h) | 300 mg Mirikizumab IV Q4W |
|---|---|
| Pharmacokinetics (PK): Clearance of Mirikizumab | 0.0224 ± 38 |
Collected over Baseline Up to week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo IV Q4W | 0/321 (0%) | 17/321 (5.3%) | 18/321 (5.6%) |
| 300 Mirikizumab IV Q4W | 0/958 (0%) | 27/958 (2.8%) | 31/958 (3.2%) |
| Placebo IV Q4W ME2 Cohort | 0/41 (0%) | 7/41 (17.1%) | 11/41 (26.8%) |
| 300 mg Mirikizumab IV Q4W ME2 Cohort | 0/125 (0%) | 10/125 (8%) | 25/125 (20%) |
| Event | Placebo IV Q4W | 300 Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 10/321 | 8/958 | 4/41 | 4/125 |
| AnaemiaBlood and lymphatic system disorders | 1/321 | 1/958 | 1/41 | 0/125 |
| PneumoniaInfections and infestations | 0/321 | 2/958 | 1/41 | 3/125 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/321 | 0/958 | 1/41 | 0/125 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/321 | 0/958 | 1/41 | 0/125 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/321 | 0/958 | 1/41 | 0/125 |
| Rectal polypGastrointestinal disorders | 0/321 | 0/958 | 0/41 | 1/125 |
| Cytomegalovirus infectionInfections and infestations | 0/321 | 0/958 | 0/41 | 1/125 |
| PharyngitisInfections and infestations | 0/321 | 0/958 | 0/41 | 1/125 |
| Joint injuryInjury, poisoning and procedural complications | 0/321 | 0/958 | 0/41 | 1/125 |
| Event | Placebo IV Q4W | 300 Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/321 | 0/958 | 4/41 | 15/125 |
| AnaemiaBlood and lymphatic system disorders | 18/321 | 31/958 | 4/41 | 8/125 |
| Colitis ulcerativeGastrointestinal disorders | 0/321 | 0/958 | 3/41 | 3/125 |
All randomized participants.
| Age, Continuous(years) | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort | Total |
|---|---|---|---|---|---|
| Mean | 41.3 ± 13.78 | 42.8 ± 13.83 | 49.4 ± 15.43 | 44.0 ± 13.88 | 42.8 ± 13.92 |
| Sex: Female, Male(Participants) | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort | Total |
|---|---|---|---|---|---|
| Female | 140 | 367 | 13 | 46 | 566 |
| Male | 182 | 592 | 28 | 79 | 881 |
| Ethnicity (NIH/OMB)(Participants) | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 22 | 0 | 0 | 31 |
| Not Hispanic or Latino | 27 | 92 | 25 | 84 | 228 |
| Unknown or Not Reported | 286 | 845 | 16 | 41 | 1188 |
| Race (NIH/OMB)(Participants) | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 10 | 0 | 0 | 12 |
| Asian | 68 | 224 | 41 | 125 | 458 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 2 | 10 | 0 | 0 | 12 |
| White | 247 | 704 | 0 | 0 | 951 |
| More than one race | 2 | 1 | 0 | 0 | 3 |
| Unknown or Not Reported | 1 | 9 | 0 | 0 | 10 |
| Region of Enrollment(Participants) | Placebo IV Q4W | 300 mg Mirikizumab IV Q4W | Placebo IV Q4W ME2 Cohort | 300 mg Mirikizumab IV Q4W ME2 Cohort | Total |
|---|---|---|---|---|---|
| Argentina | 3 | 8 | 0 | 0 | 11 |
| Australia | 4 | 10 | 0 | 0 | 14 |
| Austria | 2 | 6 | 0 | 0 | 8 |
| Belgium | 3 | 6 | 0 | 0 | 9 |
| Canada | 11 | 23 | 0 | 0 | 34 |
| China | 2 | 16 | 41 | 125 | 184 |
| Croatia | 1 | 1 | 0 | 0 | 2 |
| Czechia | 20 | 35 | 0 | 0 | 55 |
| Denmark | 0 | 7 | 0 | 0 | 7 |
| France | 15 | 49 | 0 | 0 | 64 |
| Germany | 6 | 33 | 0 | 0 | 39 |
| Hungary | 7 | 16 | 0 | 0 | 23 |
| India | 21 | 62 | 0 | 0 | 83 |
| Ireland | 0 | 1 | 0 | 0 | 1 |
| Israel | 3 | 14 | 0 | 0 | 17 |
| Italy | 12 | 25 | 0 | 0 | 37 |
| Japan | 35 | 102 | 0 | 0 | 137 |
| Latvia | 6 | 24 | 0 | 0 | 30 |
| Lithuania | 6 | 16 | 0 | 0 | 22 |
| Malaysia | 0 | 6 | 0 | 0 | 6 |
| Mexico | 2 | 10 | 0 | 0 | 12 |
| Netherlands | 2 | 9 | 0 | 0 | 11 |
| Poland | 32 | 104 | 0 | 0 | 136 |
| Romania | 2 | 13 | 0 | 0 | 15 |
| Russia | 28 | 79 | 0 | 0 | 107 |
| Serbia | 8 | 13 | 0 | 0 | 21 |
| Slovakia | 3 | 21 | 0 | 0 | 24 |
| South Korea | 5 | 23 | 0 | 0 | 28 |
| Spain | 7 | 15 | 0 | 0 | 22 |
| Switzerland | 2 | 9 | 0 | 0 | 11 |
| Taiwan | 0 | 3 | 0 | 0 | 3 |
| Turkey | 5 | 6 | 0 | 0 | 11 |
| Ukraine | 26 | 68 | 0 | 0 | 94 |
| United Kingdom | 7 | 11 | 0 | 0 | 18 |
| United States | 36 | 115 | 0 | 0 | 151 |
Showing the first 100 of 502 sites across 35 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2018 to primary completion in Jan 2021, 31 months.
Results were first posted in Feb 2022, 1 year 1 month after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 31 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab